FGP
AXSM icon

Freestone Grove Partners’s Axsome Therapeutics AXSM Stock Holding History

Freestone Grove Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$319K Buy
+1,887
New +$326K ﹤0.01% 679
2025
Q4 		– Sell
-2,494
Closed -$303K – 737
2025
Q3 		$303K Buy
+2,494
New +$281K ﹤0.01% 612

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Freestone Grove Partners's AXSM Position: Q1 2026 in Review

Freestone Grove Partners opened a new position in Axsome Therapeutics (AXSM) in Q1 2026: 1,887 shares worth $319K. The stake represents ﹤0.01% of the portfolio and ranks #679 among its holdings. This is a return to the name: Freestone Grove Partners previously reported a position in AXSM as recently as Q3 2025.

Freestone Grove Partners first reported a position in AXSM in Q3 2025 and has held it in 2 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Freestone Grove Partners held 1,887 shares of Axsome Therapeutics worth $319K as of Q1 2026.
  • Axsome Therapeutics was a new Freestone Grove Partners position in Q1 2026.
  • Axsome Therapeutics made up ﹤0.01% of Freestone Grove Partners's portfolio in Q1 2026, its #679 holding.
  • Freestone Grove Partners first reported a position in Axsome Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.